Úbytek kostní hmoty u androgen deprivační terapie: naléhavý problém pacientů s karcinomem prostaty – naše zkušenosti
| Title in English | Bone loss of androgen deprivation therapy: an urgent problem in patients with prostate cancer - our experience |
|---|---|
| Authors | |
| Year of publication | 2011 |
| Type | Article in Periodical |
| Magazine / Source | Urologické listy |
| MU Faculty or unit | |
| Citation | |
| Field | Other medical specializations |
| Keywords | androgen deprivation therapy; BMD RANKL; denosumab; prostate cancer; pathological fractures |
| Description | Androgen deprivation therapy ADT today plays a vital role in treating patients with locally advanced or metastatic prostate cancer. Bone loss due to ADT leads to increased morbidity and mortality and increased costs. In a group of 104 patients, we investigated the incidence of osteopenia and osteoporosis by measuring bone mineral density. The article offers the results of our investigation and discusses new treatment options CTIBL by a fully human monoclonal antibody denosumab |